These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 21947546)

  • 1. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin.
    Kolokoltsov AA; Adhikary S; Garver J; Johnson L; Davey RA; Vela EM
    Arch Virol; 2012 Jan; 157(1):121-7. PubMed ID: 21947546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of treatment strategies to combat Ebola and Marburg viruses.
    Paragas J; Geisbert TW
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):67-76. PubMed ID: 16441210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.
    Hulseberg CE; Fénéant L; Szymańska-de Wijs KM; Kessler NP; Nelson EA; Shoemaker CJ; Schmaljohn CS; Polyak SJ; White JM
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30700611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a broad-spectrum antiviral with activity against Ebola virus.
    Aman MJ; Kinch MS; Warfield K; Warren T; Yunus A; Enterlein S; Stavale E; Wang P; Chang S; Tang Q; Porter K; Goldblatt M; Bavari S
    Antiviral Res; 2009 Sep; 83(3):245-51. PubMed ID: 19523489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity.
    Panchal RG; Reid SP; Tran JP; Bergeron AA; Wells J; Kota KP; Aman J; Bavari S
    Antiviral Res; 2012 Jan; 93(1):23-9. PubMed ID: 22027648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus.
    Ölschläger S; Neyts J; Günther S
    Antiviral Res; 2011 Aug; 91(2):89-93. PubMed ID: 21616094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems.
    Welch SR; Guerrero LW; Chakrabarti AK; McMullan LK; Flint M; Bluemling GR; Painter GR; Nichol ST; Spiropoulou CF; Albariño CG
    Antiviral Res; 2016 Dec; 136():9-18. PubMed ID: 27771389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus.
    Müller S; Günther S
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2215-8. PubMed ID: 17371814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Viral hemorrhagic fever--Ebola hemorrhagic fever, Marburg disease and Lassa fever].
    Hotta H
    Rinsho Byori; 1998 Jul; 46(7):651-5. PubMed ID: 9721531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging intracellular receptors for hemorrhagic fever viruses.
    Jae LT; Brummelkamp TR
    Trends Microbiol; 2015 Jul; 23(7):392-400. PubMed ID: 26004032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses.
    Grant-Klein RJ; Altamura LA; Schmaljohn CS
    Virus Res; 2011 Dec; 162(1-2):148-61. PubMed ID: 21925552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples.
    Matranga CB; Andersen KG; Winnicki S; Busby M; Gladden AD; Tewhey R; Stremlau M; Berlin A; Gire SK; England E; Moses LM; Mikkelsen TS; Odia I; Ehiane PE; Folarin O; Goba A; Kahn SH; Grant DS; Honko A; Hensley L; Happi C; Garry RF; Malboeuf CM; Birren BW; Gnirke A; Levin JZ; Sabeti PC
    Genome Biol; 2014; 15(11):519. PubMed ID: 25403361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus.
    Chen D; Hou Z; Jiang D; Zheng M; Li G; Zhang Y; Li R; Lin H; Chang J; Zeng H; Guo JT; Zhao X
    Emerg Microbes Infect; 2019; 8(1):1511-1523. PubMed ID: 31631785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral haemorrhagic fevers caused by Lassa, Ebola and Marburg viruses.
    Curtis N
    Adv Exp Med Biol; 2006; 582():35-44. PubMed ID: 16802617
    [No Abstract]   [Full Text] [Related]  

  • 15. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.
    Safronetz D; Rosenke K; Westover JB; Martellaro C; Okumura A; Furuta Y; Geisbert J; Saturday G; Komeno T; Geisbert TW; Feldmann H; Gowen BB
    Sci Rep; 2015 Oct; 5():14775. PubMed ID: 26456301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule inhibitors of ebola virus infection.
    Picazo E; Giordanetto F
    Drug Discov Today; 2015 Feb; 20(2):277-86. PubMed ID: 25532798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug targets in infections with Ebola and Marburg viruses.
    Gene OG; Julia BE; Vanessa MR; Victoria WJ; Thomas GW; Lisa HE
    Infect Disord Drug Targets; 2009 Apr; 9(2):191-200. PubMed ID: 19275706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
    Zhu X; Yao C; Wei Y; Kou Z; Hu K
    Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QnAs with Pardis Sabeti.
    Ravindran S
    Proc Natl Acad Sci U S A; 2017 Sep; 114(37):9757-9758. PubMed ID: 28874553
    [No Abstract]   [Full Text] [Related]  

  • 20. [Research with the Marburg, Lassa and Ebola viruses].
    Pshenichnov VA; Makhlaĭ AA; Mikhaĭlov VV
    Vopr Virusol; 1993; 38(2):54-8. PubMed ID: 8059520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.